Importer of Controlled Substances Application: Globyz Pharma, LLC; Correction
---
identifier: "/us/fr/2022-00852"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Importer of Controlled Substances Application: Globyz Pharma, LLC; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "2022-00852"
section_name: "Importer of Controlled Substances Application: Globyz Pharma, LLC; Correction"
positive_law: false
currency: "2022-01-24"
last_updated: "2022-01-24"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Justice Department"
document_number: "2022-00852"
document_type: "notice"
publication_date: "2022-01-24"
agencies:
- "Justice Department"
- "Drug Enforcement Administration"
fr_citation: "87 FR 3587"
fr_volume: 87
docket_ids:
- "Docket No. DEA-875"
fr_action: "Notice of application; correction."
---
# Importer of Controlled Substances Application: Globyz Pharma, LLC; Correction
**AGENCY:**
Drug Enforcement Administration, Justice.
**ACTION:**
Notice of application; correction.
**SUMMARY:**
The Drug Enforcement Administration (DEA) published a document in the *Federal Register* on August 12, 2021, concerning a notice of application. The document indicated the approved drug code (1205—Lisdexamfetamine) as a schedule I. The correct drug schedule should read schedule II.
**SUPPLEMENTARY INFORMATION:**
**Correction**
In the *Federal Register* of August 12, 2021, in FR Doc. 2021-17181 (86 FR 44405), on page 44406, in the first column, in the controlled substance table, correct the drug schedule to schedule II.
Brian S. Besser,
Acting Assistant Administrator.